Caresyntax and The Jacobs Institute Join Forces to Enhance Surgical Insights Using Real-World Evidence

Strategic Collaboration to Advance Surgical Insights

In an exciting development for the medical technology industry, Caresyntax Corporation, a pioneer in the integration and intelligence of surgical data, has partnered with The Jacobs Institute, a renowned not-for-profit organization specializing in vascular medical technology innovation. Announced on May 6, 2025, this strategic collaboration aims to significantly enhance the utilization of Real-World Evidence (RWE) within the scope of product evaluation and patient outcomes improvement.

What This Partnership Entails

The Jacobs Institute is now a vital member of the Caresyntax Clinical Innovation Network. This unique collaboration combines Caresyntax's proprietary data science and established methodologies for real-world evidence with the clinical expertise and innovative infrastructure of The Jacobs Institute, particularly in the realm of vascular surgery. The partnership is designed to streamline and enrich the evaluation of surgical procedures and medical devices through a vendor-neutral RWE engine.

The Caresyntax Clinical Innovation Network consists of a group of forward-thinking healthcare institutions that are dedicated to fostering data-driven decision-making in healthcare. Through their participation, members have access to the entire suite of Clinical Quality Improvement (CQI) partnerships offered by Caresyntax. Within CQI projects, Caresyntax gathers, organizes, and analyzes real-world data for medical technology partners to gain deeper insights into the factors that affect patient experiences during surgery. This provides MedTech innovators with a cost-effective and patient-centered alternative to traditional clinical trials, thereby expediting the adoption and effective use of new medical devices.

Matt Krueger, President of Caresyntax, expressed enthusiasm about the partnership, stating, “We are thrilled to partner with The Jacobs Institute, a true pioneer in clinical innovation. With its integrated network of clinical, engineering, and industry knowledge, JI is a natural fit for our clinical innovation network. The Jacobs Institute significantly enhances our ability to generate deep, procedural insights and to connect innovative companies to the real-world evidence they need.”

The Jacobs Institute's Perspective

The Jacobs Institute aligns this collaboration with its mission to advance models that study innovations in vascular disease. As a research institution at the forefront of surgical care, JI aims to leverage this partnership to improve patient outcomes significantly. Dr. Adnan H. Siddiqui, CEO and CMO of The Jacobs Institute, highlighted the importance of this collaboration, saying, “Partnering with Caresyntax provides a powerful new tool to take our relationships with industry partners to the next level. This collaboration enables us to support the broader healthcare ecosystem by facilitating the generation of high-quality Real-World Evidence, which is essential for advancing medical technology and improving patient care standards globally. We look forward to seeing the positive impact of this initiative.”

The Significance of This Collaboration

This partnership represents a major advancement in enhancing clinical quality improvement, utilizing data curation algorithms and sophisticated data system science designed to elevate surgical care and expedite the development of effective medical technologies. Through this initiative, both Caresyntax and The Jacobs Institute are not only committed to better surgical outcomes but also to the overall enhancement of the healthcare landscape.

About Caresyntax

Based in San Francisco and Berlin, Caresyntax aims to make surgery both smarter and safer. Their software operates in over 4,200 operating rooms globally, contributing to more than three million surgical procedures annually. Additional information can be found at Caresyntax.com.

About The Jacobs Institute

The Jacobs Institute is dedicated to fostering the development of the next generation of technologies in vascular and neurologic medicine. By promoting collaboration between physicians, engineers, entrepreneurs, and industry stakeholders, JI contributes to improving treatment for vascular diseases both locally and globally. More information can be found at Jacobsinstitute.org.